KMT2A and acute lymphoblastic leukemia: The RBP insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has similarly been found to be overexpressed in mixed-lineage leukemia–rearranged (MLL rearranged) B-acute lymphoblastic leukemia (B-ALL) and to be associated with poorer outcomes and higher recurrence risks in these patients [12].